1. Home
  2. BTMD vs MAIA Comparison

BTMD vs MAIA Comparison

Compare BTMD & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biote Corp.

BTMD

Biote Corp.

HOLD

Current Price

$2.21

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.30

Market Cap

77.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTMD
MAIA
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.0M
77.1M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
BTMD
MAIA
Price
$2.21
$1.30
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$2.83
N/A
AVG Volume (30 Days)
209.8K
925.5K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
722.22
33.33
EPS
0.06
N/A
Revenue
$192,219,000.00
N/A
Revenue This Year
$2.03
N/A
Revenue Next Year
$6.58
N/A
P/E Ratio
$39.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.27
$0.87
52 Week High
$4.75
$3.19

Technical Indicators

Market Signals
Indicator
BTMD
MAIA
Relative Strength Index (RSI) 54.83 47.39
Support Level $1.97 $1.21
Resistance Level $2.79 $1.49
Average True Range (ATR) 0.15 0.10
MACD 0.02 0.00
Stochastic Oscillator 58.72 20.73

Price Performance

Historical Comparison
BTMD
MAIA

About BTMD Biote Corp.

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: